Compare Cassava Sciences Inc (FLNA) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while YieldMax TSLA Option Income Strategy ETF trades at $26.14. Which is the better fit depends on your goals.
| FLNA | TSLY | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $4.64 | $48.25 |
52-Week Low | $1.09 | $26.16 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
TSLY trades at $26.48, down 1.3% over the past day, with a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a high distribution yield, with recent weekly dividends ranging from $0.26 to $0.52. Recent news highlights consistent distribution announcements from YieldMax, though coverage notes the fund's capped upside and volatility risks tied to its synthetic TSLA exposure.
The outlook for TSLY hinges on its ability to sustain high yields through option income strategies, but faces risks from Tesla's stock volatility and potential capital erosion. Investors should weigh the attractive income against significant downside exposure and limited growth potential in a bearish technical environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
